Trexject is a range of pre-filled Methotrexate syringes approved by the Therapeutic Goods Administration (TGA) in Australia, and provides an option for patients who do not want the inconvenience of filling their own syringes. However, Trexject is not currently listed on the Pharmaceutical Benefits Scheme (PBS), which means it is very expensive, forcing many patients to remain with a less desirable or convenient option.
The Pharmaceutical Benefits Advisory Committee (PBAC), which make recommendations for listing medicines on the PBS, will review Trexject in March 2017. CreakyJoints Australia wants patients to have affordable, easy options for managing their condition. On 8th February CreakyJoints Australia submitted comments in favour of Trexject being included on the PBS. (This does not constitute an endorsement of the brand, but speaks to the need for all delivery mechanisms to be equally available and accessible to Australian patients.)
To support our submission we ran a poll and asked you why it is important that pre-filled Methotrexate syringes are made more accessible and affordable to Australians. We had 56 responses that were all in favour of supporting pre-filled Methotrexate syringes as well as many insightful comments.
We will share the outcomes after the March meeting.
